Dependence of aldehyde dehydrogenase-mediated oxazaphosphorine resistance on soluble thiols importance of thiol interactions with the secondary metabolite acrolein

Biochemical Pharmacology

Volumn 56, Issue 1, 1998, Pages 31-39

  Bunting, Kevin D ^a,b   Townsend, Alan J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

4 Hydroperoxycyclophosphamide; Acrolein; Aldehyde dehydrogenase; Drug resistance; Glutathione; Mafosfamide

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ACETYLCYSTEINE; ACROLEIN; ALDEHYDE DEHYDROGENASE; DRUG METABOLITE; GLUTATHIONE; MAFOSFAMIDE; MESNA; OXAZAPHOSPHORINE; THIOL GROUP;

ARTICLE; CYTOTOXICITY; DRUG RESISTANCE; HAMSTER; LUNG FIBROBLAST; PRIORITY JOURNAL;

ACROLEIN; ALDEHYDE DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE; CRICETINAE; CRICETULUS; GLUTATHIONE; HUMANS; ISOENZYMES; SULFHYDRYL COMPOUNDS;

EID: 0031750681     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00111-7     Document Type: Article

References (55)

1. Colvin OM and Chabner B, Alkylating agents. In: Cancer Chemotherapy: Principles and Practice. (Eds. Chabner BA and Collins JM), pp. 276-313. J.B. Lippincott, Philadelphia, PA, 1990.
2. Colvin M and Hilton J, Pharmacology of cyclophosphamide and metabolites. Cancer Treat Rep 65 ((Suppl 3)):89, 1982.
3. Sladek NE, Metabolism of oxazaphosphorines. Pharmacol Ther 37: 301-355, 1988.
4. Hilton J, Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 44: 5156-5160, 1984.
5. Hilton J, Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and -resistant L1210 cells. Biochem Pharmacol 33: 1867-1872, 1984.
6. Russo J, Hilton J and Colvin OM, The role of aldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide. In: Enzymology and Molecular Biology of Carbonyl Metabolism (Eds. Weiner H and Flynn TG), Vol. 2, pp. 65-79. Alan R. Liss, New York, 1989.
7. Frei EI, Teicher BA, Holden SA, Cathcart KNS and Wang Y, Preclinical studies and correlation of the effect of alkylating dose. Cancer Res 48: 6417-6423, 1988.
8. Sreerama L and Sladek NE, Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem Pharmacol 45: 2487-2505, 1993.
9. Sreerama L and Sladek NE, Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Cancer Res 54: 2176-2185, 1994.
10. Sreerama L and Sladek NE, Identification of the class-3 aldehyde dehydrogenases present in human MCF-7/0 breast adenocarcinoma cells and normal human breast tissue. Biochem Pharmacol 48: 617-620, 1994.
11. Rekha GK, Sreerama L and Sladek NE, Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. Biochem Pharmacol 48: 1943-1952, 1994.
12. Bunting KD and Townsend AJ, De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines. J Biol Chem 271: 11884-11890, 1996.
13. Bunting KD and Townsend AJ, Protection by transfected rat or human class 3 aldehyde dehydrogenases against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. J Biol Chem 271: 11891-11896, 1996.
14. Santos GW and Colvin OM, Pharmacological purging of bone marrow with reference to autografting. Clin Haematol 15: 67-83, 1986.
15. Hilgard P and Pohl J, Oxazaphosphorine toxicity reduction by mesna. Cancer Treat Rev 17: 217-220, 1990.
16. Halliwell B and Gutteridge JMC, Oxygen free radicals and iron in relation to biology and medicine: Some problems and concepts. Arch Biochem Biophys 246: 501-514, 1986.
17. Meister A, Glutathione deficiency produced by inhibition of its synthesis, and its reversal; Applications in research and therapy. Pharmacol Ther 51: 155-194, 1991.
18. Chen G and Waxman DJ, Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Biochem Pharmacol 47: 1079-1087, 1994.
19. Anderson M and Meister A, Glutathione monoesters. Anal Biochem 183: 16-20, 1989.
20. Anderson M, Powrie F, Puri R and Meister A, Glutathione monoethyl ester: Preparation, uptake by tissues, and conversion to glutathione. Arch Biochem Biophys 239: 538-548, 1985.
21. Williamson JM, Boettcher B and Meister A, Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis. Proc Natl Acad Sci USA 79: 6246-6249, 1982.
22. Williamson J and Meister A, Stimulation of hepatic glutathione formation by administration of L-2-oxothiazolidine-4-carboxylate, a 5-oxo-L-prolinase substrate. Proc Natl Acad Sci USA 78: 936-939, 1981.
23. Russo A and Mitchell J, Potentiation and protection of doxorubicin cytotoxicity by cellular glutathione modulation. Cancer Treat Rep 69: 1293-1296, 1985.
24. Russo A, DeGraff W, Friedman N and Mitchell J, Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res 46: 2845-2848, 1986.
25. Anderson ME and Meister A, Transport and direct utilization of γ-glutamylcyst(e)ine for glutathione synthesis. Proc Natl Acad Sci USA 80: 707-711, 1983.
26. Crook T, Souhami R, Whymann G and McLean A, Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide. Cancer Res 46: 5035-5038, 1986.
27. Chenna A, Rieger RA and Iden CR, Characterization of thymidine adducts formed by acrolein and 2-bromoacrolein. Carcinogenesis 13: 2361-2365, 1992.
28. Adams JJ and Klaidman LK, Acrolein-induced oxygen radical formation. Free Radic Biol Med 15: 187-193, 1993.
29. Crook TR, Souhami RL and McLean AEM, Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res 46: 5029-5034, 1986.
30. Smith RA, Cohen SM and Lawson TA, Acrolein mutagenicity in the V79 assay. Carcinogenesis 11: 497-498, 1990.
31. Petersen DR, Hjelle JJ and Mitchell DY, Aldehydic products of lipid peroxidation: Substrates or inhibitors of hepatic aldehyde dehydrogenase? Adv Exp Med Biol 284: 67-73, 1991.
32. Mitchell DY and Petersen DR, Inhibition of rat liver mitochondrial and cytosolic aldehyde dehydrogenases by crotonaldehyde. Drug Metab Dispos 21: 396-399, 1993.
33. 1. Proc Natl Acad Sci USA 85: 5769-5773, 1988.
34. Townsend AJ, Tu C-PD and Cowan KH, Expression of human μ or α class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells: Effect on cellular sensitivity to cytotoxic agents. Mol Pharmacol 41: 230-236, 1992.
35. Bunting KD, Lindahl R and Townsend AJ, Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase. J Biol Chem 269: 23197-23203, 1994.
36. Manthey CL and Sladek NE, Kinetic characterization of the catalysis of "activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) by mouse hepatic aldehyde dehydrogenases. Biochem Pharmacol 37: 2781-2790, 1988.
37. Witz G, Biological interactions of α,β-unsaturated aldehydes. Free Radic Biol Med 7: 333-349, 1989.
38. Chatterjee S, Hirschler NV, Petzold SJ, Berger SJ and Berger NA, Mutant cells defective in poly(ADP-ribose) synthesis due to stable alterations in enzyme activity or substrate availability. Exp Cell Res 184: 1-15, 1989.
39. Tietze F, Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal Biochem 27: 502-522, 1969.
40. Mitchell DY and Petersen DR, Inhibition of rat liver aldehyde dehydrogenases by acrolein. Drug Metab Dispos 16: 37-42, 1988.
41. Mitchell D and Petersen D, Metabolism of the glutathione-acrolein adduct, S-(2-aldehydoethyl)glutathione, by rat liver alcohol and aldehyde dehydrogenase. J Pharmacol Exp Ther 251: 193-198, 1989.
42. Sladek NE, Low JE and Landkamer GJ, Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines. Cancer Res 45: 625-629, 1985.
43. Richardson M and Siemann D, Thiol manipulation as a means of overcoming drug resistance in a novel cyclophosphamide-induced resistant cell line. Int J Radiat Oncol Biol Phys 22: 781-784, 1991.
44. Dorr RT and Lagel K, Effect of sulfhydryl compounds and glutathione depletion on rat heart myocyte toxicity induced by 4-hydroperoxycyclophosphamide and acrolein in vitro. Chem Biol Interact 93: 117-128, 1994.
45. Colvin OM, Friedman HS, Gamcsik MP, Fenselau C and Hilton J, Role of glutathione in cellular resistance to alkylating agents. Adv Enzyme Regul 33: 19-26, 1993.
46. Schröder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC and Ozols RF, Glutathione and drug resistance. Cancer Invest 14: 158-168, 1996.
47. Sinha BK and Mimnaugh EG, Free radicals and anticancer drug resistance: Oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radic Biol Med 8: 567-581, 1990.
48. Lee FYF, Flannery DJ and Siemann DW, Prediction of tumour sensitivity to 4-hydroperoxycyclophosphamide by a glutathione-targeted assay. Br J Cancer 63: 217-222, 1991.
49. Dirven HAAM, van Ommen B and van Bladeren PJ, Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 54: 6215-6220, 1994.
50. Yuan ZM, Smith PB, Brundrett RB, Colvin M and Fenselau C, Glutahione conjugation with phosphoramide mustard and cyclophosphamide: A mechanistic study using tandem mass spectrometry. Drug Metab Dispos 19: 625-629, 1991.
51. Lee F, Glutathione diminishes the anti-tumour activity of 4-hydroperoxycyclophosphamide by stabilising its spontaneous breakdown to alkylating metabolites. Br J Cancer 63: 45-50, 1991.
52. Pietruszko R, Blatter E, Abriola DP and Prestwich G, Localization of cysteine 302 at the active site of aldehyde dehydrogenase. Adv Exp Med Biol 284: 19-30, 1991.
53. Parsons PG, Lean J, Kable EPW, Favier D, Khoo SK, Hurst T, Holmes RS and Bellet AJD, Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines. Biochem Pharmacol 40: 2641-2649, 1990.
54. Hartley DP, Lindahl R and Petersen DR, Covalent modification of class 2 and class 3 aldehyde dehydrogenase by 4-hydroxynonenal. Adv Exp Med Biol 372: 93-102, 1995.
55. Kohn FR, and Sladek NE, Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines. Biochemical Pharmacology 34: 3465-3471, 1985.